Enterobacteriaceae producing extended spectrum beta-lactamase: Epidemiology, risk factors, and prevention;Entérobactéries productrices de bêta-lactamases à spectre élargi: Épidémiologie, facteurs de risque et mesures de prévention

Revue de Medecine Interne

Volumn 34, Issue 11, 2013, Pages 687-693

  Vodovar, D ^a   Marcade G ^a   Raskine, L ^a   Malissin, I ^a   Megarbane B ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bact ries multir sistantes; B ta lactamase spectre largi; Carbap n me; Carbapeneme; Ent robact rie; Enterobacteriaceae; Extended spectrum beta lactamase; Infection nosocomiale; Multiresistant bacteria; Nosocomial infection; Pr vention; Prevention

Indexed keywords

BACTERIUM ISOLATION; COMMUNICABLE DISEASE; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; HYGIENE; INAPPROPRIATE PRESCRIBING; INFECTION PREVENTION; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; SHORT SURVEY;

BACTÉRIES MULTIRÉSISTANTES; BÊTA-LACTAMASE À SPECTRE ÉLARGI; CARBAPENEME; CARBAPÉNÈME; ENTEROBACTERIACEAE; ENTÉROBACTÉRIE; EXTENDED SPECTRUM BETA-LACTAMASE; INFECTION NOSOCOMIALE; MULTIRESISTANT BACTERIA; NOSOCOMIAL INFECTION; PREVENTION; PRÉVENTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FRANCE; GEOGRAPHY; HUMANS; RISK FACTORS;

EID: 84887146201     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.10.365     Document Type: Short Survey

References (82)

1. Jarlier V., Trystram D., Brun-Buisson C., Fournier S., Carbonne A., Marty L., et al. Curbing methicillin-resistant Staphylococcus aureus in 38French hospitals through a 15-year institutional control program. Arch Intern Med 2010, 170(6):552-559.
2. Datta N., Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 1965, 208(5007):239-241.
3. Ruppé E. Epidemiology of expanded-spectrum beta-lactamases: the rise of CTX-M. Antibiotiques 2010, 12:3-16.
4. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11(6):315-317.
5. Philippon A., Labia R., Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1989, 33(8):1131-1136.
6. Ambler R.P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 1980, 289(1036):321-331.
7. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39(6):1211-1233.
8. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18(4):657-686.
9. Jarlier V., Nicolas M.H., Fournier G., Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988, 10(4):867-878.
10. Drieux L., Brossier F., Sougakoff W., Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008, 14(Suppl. 1):90-103.
11. Comité de l'antibiogramme de la société française de microbiologie. Recommendation du comité de l'antibiogramme de la société française de microbiologie 2011.
12. Pitout J.D.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8(3):159-166.
13. Observatoire National de l'Epidémiologie de la Résistance Bactérienne aux Antibiotiques (ONERBA) Annual report 2010.
14. Silva-Sanchez J., Barrios H., Reyna-Flores F., Bello-Diaz M., Sanchez-Perez A., Rojas T., et al. Prevalence and characterization of plasmid-mediated quinolone resistance genes in extended-spectrum β-lactamase-producing enterobacteriaceae isolates in Mexico. Microbial Drug Resistance 2011, 17(4):497-505.
15. Falagas M.E., Karageorgopoulos D.E. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009, 73(4):345-354.
16. Valverde A., Coque T.M., Sánchez-Moreno M.P., Rollán A., Baquero F., Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004, 42(10):4769-4775.
17. Rogers B.A., Sidjabat H.E., Paterson D.L. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66(1):1-14.
18. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim. Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007, 60(5):1018-1029.
19. Bell J.M., Turnidge J.D., Gales A.C., Pfaller M.A., Jones R.N. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-1999). Diagn Microbiol Infect Dis 2002, 42(3):193-198.
20. Gagliotti C., Balode A., Baquero F., Degener J., Grundmann H., Gür D., et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002to 2009. Euro Surveill 2011, 16(11).
21. Ruppé E., Woerther P.L., Diop A., Sene A.M., Da Costa A., Arlet G., et al. Carriage of CTX-M-15-producing Escherichia coli isolates among children living in a remote village in Senegal. Antimicrob Agents Chemother 2009, 53(7):3135-3137.
22. Woerther P.L., Angebault C., Lescat M., Ruppé E., Skurnik D., Mniai A.E., et al. Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population. J Infect Dis 2010, 202(4):515-523.
23. Luvsansharav U.O., Hirai I., Niki M., Nakata A., Yoshinaga A., Moriyama T., et al. Prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother 2011, 17(5):722-725.
24. Luvsansharav U.O., Hirai I., Niki M., Sasaki T., Makimoto K., Komalamisra C., et al. Analysis of risk factors for a high prevalence of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in asymptomatic individuals in rural Thailand. J Med Microbiol 2011, 60(Pt. 5):619-624.
25. Kader A.A., Kumar A., Kamath K.A. Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007, 28(9):1114-1116.
26. Janvier F., Mérens A., Delaune D., Soler C., Cavallo J.D. Fecal carriage of third generation cephalosporins resistant Enterobacteteriaceae in asymptomatic young adults: evolution between 1999and 2009. Pathol Biol 2011, 59(2):97-101.
27. Andriatahina T., Randrianirina F., Hariniana E.R., Talarmin A., Raobijaona H., Buisson Y., et al. High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar. BMC Infect Dis 2010, 10:204.
28. Tandé D., Jallot N., Bougoudogo F., Montagnon T., Gouriou S., Sizun J. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in a Malian orphanage. Emerging Infect Dis 2009, 15(3):472-474.
29. Doi Y., Adams-Haduch J.M., Shivannavar C.T., Paterson D.L., Gaddad S.M. Faecal carriage of CTX-M-15-producing Klebsiella pneumoniae in patients with acute gastroenteritis. Indian J Med Res 2009, 129(5):599-602.
30. Lo W.U., Ho P.L., Chow K.H., Lai E.L., Yeung F., Chiu S.S. Fecal carriage of CTX-M type extended-spectrum beta-lactamase-producing organisms by children and their household contacts. J Infect 2009, 60(4):286-292.
31. Friedmann R., Raveh D., Zartzer E., Rudensky B., Broide E., Attias D., et al. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol 2009, 30(6):534-542.
32. Harris A.D., Nemoy L., Johnson J.A., Martin-Carnahan A., Smith D.L., Standiford H., et al. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 2004, 25(2):105-108.
33. Castillo García F.J., Seral García C., Pardos De la Gandara M., Millán Lou M.I., Pitart Ferré C. Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods. Eur J Clin Microbiol Infect Dis 2007, 26(1):77-78.
34. Arnan M., Gudiol C., Calatayud L., Liñares J., Dominguez MÁ, Batlle M., et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011, 30(3):355-360.
35. Tham J., Odenholt I., Walder M., Brolund A., Ahl J., Melander E. Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis 2010, 42(4):275-280.
36. Rooney P.J., O'Leary M.C., Loughrey A.C., McCalmont M., Smyth B., Donaghy P., et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009, 64(3):635-641.
37. Valverde A., Coque T.M., Sánchez-Moreno M.P., Rollán A., Baquero F., Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during non outbreak situations in Spain. J Clin Microbiol 2004, 42(10):4769-4775.
38. Réseau BMR-Raisin. Surveillance des bactéries multi résistantes dans les établissements de santé en France 2009.
39. Arpin C., Quentin C., Grobost F., Cambau E., Robert J., Dubois V., et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009, 63(6):1205-1214.
40. Quentin C., Arpin C., Dubois V., André C., Lagrange I., Fischer I., et al. Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice. Eur J Clin Microbiol Infect Dis 2004, 23(3):185-193.
41. Ruppé E., Pitsch A., Tubach F., de Lastours V., Chau F., Pasquet B., et al. Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards. Eur J Clin Microbiol Infect Dis 2011, 31(3):319-325.
42. Troché G., Joly L.M., Guibert M., Zazzo J.F. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 2005, 26(2):161-165.
43. Lawrence C., Ohana S., Ronco E., Dizien O., Denys P., Laffont I., et al. Routine screening of antibiotic-resistant bacteria in acute rehabilitation units. Pathol Biol 2004, 52(10):602-606.
44. Laupland K.B., Church D.L., Vidakovich J., Mucenski M., Pitout J.D.D. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008, 57(6):441-448.
45. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60(5):913-920.
46. Qureshi Z.A., Paterson D.L., Pakstis D.L., Adams-Haduch J.M., Sandkovsky G., Sordillo E., et al. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents 2011, 37(1):26-32.
47. Kola A., Maciejewski O., Sohr D., Ziesing S., Gastmeier P. Clinical impact of infections caused by ESBL-producing E.coli and K.pneumoniae. Scand J Infect Dis 2007, 39(11-12):975-982.
48. Yang Y.S., Ku C.H., Lin J.C., Shang S.T., Chiu C.H., Yeh K.M., et al. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect 2010, 43(3):194-199.
49. Haut conseil de la santé publique Recommandations relatives aux mesures à mettre en œuvre pour prévenir l'émergence des entérobactéries BLSE et lutter contre leur dissémination 2010.
50. Nseir S., Blazejewski C., Lubret R., Wallet F., Courcol R., Durocher A. Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect 2011, 17(8):1201-1208.
51. Harris A.D., Kotetishvili M., Shurland S., Johnson J.A., Morris J.G., Nemoy L.L. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 2007, 35(2):97-101.
52. Overdevest I., Willemsen I., Rijnsburger M., Eustace A., Xu L., Hawkey P., et al. Extended-spectrum β-lactamase genes of Escherichia coli in chicken meat and humans, The Netherlands. Emerging Infect Dis 2011, 17(7):1216-1222.
53. Timofte D., Dandrieux J., Wattret A., Fick J., Williams N.J. Detection of extended-spectrum-{beta}-lactamase-positive Escherichia coli in bile isolates from two dogs with bacterial cholangiohepatitis. J Clin Microbiol 2011, 49(9):3411-3414.
54. Luo Y., Cui S., Li J., Yang J., Lin L., Hu C., et al. Characterization of Escherichia coli isolates from healthy food handlers in hospital. Microb Drug Resist 2011, 17(3):443-448.
55. Bellini C, Nahimana I, Senn L, Wenger P, Francioli P, Zanetti G.Enterobacteriaceae producing extended-spectrum beta-lactamase: duration of carriage and implication for surveillance. 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona. 2008.
56. Kola A., Holst M., Chaberny I.F., Ziesing S., Suerbaum S., Gastmeier P. Surveillance of extended-spectrum beta-lactamase-producing bacteria and routine use of contact isolation: experience from a three-year period. J Hosp Infect 2007, 66(1):46-51.
57. Agence française de sécurité sanitaire et des produits de santé Dix ans d'évolution des consommations d'antibiotiques en France 2009.
58. European Antimicrobial Resistance Surveillance Network Antimicrobial resistance surveillance in Europe 2009 2009.
59. The bacterial challenge: time to react: a call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents 2009, ECDC/EMEA Joint Working Group.
60. Agence française de sécurité sanitaire et des produits de santé Émergence des bacteries multi-resistantes - Importance renforcee du bon usage des antibiotiques 2011.
61. Zahar J.R., Mamzer M.F., Kouatchet A. Contact isolation in the intensive care unite: why, when and adverse effects. Reanimation 2011, 21(Suppl. 2):494-502.
62. Evans H.L., Shaffer M.M., Hughes M.G., Smith R.L., Chong T.W., Raymond D.P., et al. Contact isolation in surgical patients: a barrier to care?. Surgery 2003, 134(2):180-188.
63. Saint S., Higgins L.A., Nallamothu B.K., Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control 2003, 31(6):354-356.
64. Stelfox H.T., Bates D.W., Redelmeier D.A. Safety of patients isolated for infection control. JAMA 2003, 290(14):1899-1905.
65. Kennedy P., Hamilton L.R. Psychological impact of the management of methicillin-resistant Staphylococcus aureus (MRSA) in patients with spinal cord injury. Spinal Cord 1997, 35(9):617-619.
66. Lefort A. Modification des valeurs critiques: le point de vue du clinicien. 31e réunion interdisciplinaire de chimiothérapie anti-infectieuse. Paris. 2011.
67. Hawser S., Hoban D., Bouchillon S., Badal R., Carmeli Y., Hawkey P. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect 2011, 30(2):173-179.
68. Rhomberg P.R., Jones R.N. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009, 65(4):414-426.
69. Rodríguez-Baño J., Navarro M.D., Romero L., Muniain M.A., Perea E.J., Pérez-Cano R., et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006, 42(1):37-45.
70. Waltner-Toews R.I., Paterson D.L., Qureshi Z.A., Sidjabat H.E., Adams-Haduch J.M., Shutt K.A., et al. Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1hyperproduction. Antimicrob Agents Chemother 2011, 55(2):495-501.
71. Mehrgan H., Rahbar M., Arab-Halvaii Z. High prevalence of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Tehran. Iran. J Infect Dev Ctries 2010, 4(3):132-138.
72. Shanthi M., Sekar U. Extended spectrum-beta-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. J Assoc Physicians India 2010, 58:41-44.
73. Azim A., Dwivedi M., Rao P.B., Baronia A.K., Singh R.K., Prasad K.N., et al. Epidemiology of bacterial colonization at intensive care unit admission with emphasis on extended-spectrum beta-lactamase-and metallo-beta-lactamase-producing Gram-negative bacteria-an Indian experience. J Med Microbiol 2010, 59(Suppl. 8):955-960.
74. Shigehara K., Uchibayashi T., Maeda E., Namiki M. Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors. Int J Urol 2009, 16(10):808-812.
75. Demirdag K., Hosoglu S. Epidemiology and risk factors for ESBL-producing Klebsiella pneumoniae: a case control study. J Infect Dev Ctries 2010, 4(11):717-722.
76. Wener K.M., Schechner V., Gold H.S., Wright S.B., Carmeli Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother 2010, 54(5):2010-2016.
77. Ortega M., Marco F., Soriano A., Almela M., Martínez J.A., Muñoz A., et al. Analysis of 4758Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009, 63(3):568-574.
78. Mosqueda-Gómez J.L., Montaño-Loza A., Rolón A.L., Cervantes C., Bobadilla-del-Valle J.M., Silva-Sánchez J., et al. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. A case-control study. Int J Infect Dis 2008, 12(6):653-659.
79. Lin M.F., Huang M.L., Lai S.H. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003, 53(1):39-45.
80. Du B., Long Y., Liu H., Chen D., Liu D., Xu Y., et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002, 28(12):1718-1723.
81. Martínez J.A., Aguilar J., Almela M., Marco F., Soriano A., López F., et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006, 58(5):1082-1085.
82. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32(8):1162-1171.